Literature DB >> 26795873

Immunological basis for treatment of graft versus host disease after liver transplant.

Vikrant Rai1, Nicholas Edward Dietz2, Devendra K Agrawal1.   

Abstract

Graft versus host disease (GVHD) after liver transplant, although a rare disease, has a very high mortality rate. GVHD occurs due to immunoreactions caused by donor T lymphocytes and host cell surface antigens resulting in proliferation and clonal expansion of T lymphocyte. Migration of effector cells, including macrophages, NK cells and cytotoxic T lymphocyte, to the target organs such as skin, intestine and bone marrow results in skin rashes, diarrhea and bone marrow depression. GVHD is diagnosed by clinical symptoms, histopathological findings and by the presence of chimerism. The delayed diagnosis, opportunistic infections and lack of definitive treatment of post orthotopic liver transplant (OLT)-GVHD results in sepsis and multi-organ failure leading to very low survival rates. In this review, we have focused on early diagnosis and critically discuss novel treatment modalities to decrease the incidence of GVHD.

Entities:  

Keywords:  Chimerism; Graft versus host disease; Immunoreactivity; Multi organ failure; Opportunistic infections; Sepsis; Surface antigens; T lymphocytes; liver transplant

Mesh:

Year:  2016        PMID: 26795873      PMCID: PMC4955803          DOI: 10.1586/1744666X.2016.1145056

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  96 in total

Review 1.  Microchimerism, GVHD, and tolerance in solid organ transplantation.

Authors:  D J Triulzi; M A Nalesnik
Journal:  Transfusion       Date:  2001-03       Impact factor: 3.157

2.  Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator?

Authors:  Guido Junge; U P Neumann; M Joka; M Nagy; R Neuhaus; J M Langrehr; P Neuhaus
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

3.  Successful outcome of acute graft-versus-host disease in a liver allograft recipient by withdrawal of immunosuppression.

Authors:  F Lehner; T Becker; L Sybrecht; R Lück; R Schwinzer; K Slateva; R Blasczyk; B Hertenstein; J Klempnauer; B Nashan
Journal:  Transplantation       Date:  2002-01-27       Impact factor: 4.939

4.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

5.  Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation.

Authors:  Zhenhua Hu; Ze Qian; Jian Wu; Jie Zhou; Min Zhang; Lin Zhou; Shusen Zheng
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-09-14       Impact factor: 2.947

6.  Graft-versus-host disease presenting with pancytopenia after en bloc multiorgan transplantation: case report and literature review.

Authors:  R Mawad; A Hsieh; L Damon
Journal:  Transplant Proc       Date:  2009-12       Impact factor: 1.066

Review 7.  Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients.

Authors:  Edie Y Chan; Anne M Larson; Terry B Gernsheimer; Kris V Kowdley; Robert L Carithers; Jorge D Reyes; James D Perkins
Journal:  Liver Transpl       Date:  2007-04       Impact factor: 5.799

8.  Abatacept use in graft-versus-host disease after orthotopic liver transplantation: a case report.

Authors:  M A Elfeki; P V Genco; S Pungpapong; R E Nakhleh; J H Nguyen; D M Harnois
Journal:  Transplant Proc       Date:  2014-09       Impact factor: 1.066

Review 9.  Graft versus host disease after liver transplantation - a single center experience and review of literature.

Authors:  Sven Kohler; Andreas Pascher; Guido Junge; Igor M Sauer; Marion Nagy; Constanze Schönemann; Martin Koch; Ulf Neumann; Johann Pratschke; Peter Neuhaus
Journal:  Transpl Int       Date:  2008-02-04       Impact factor: 3.782

Review 10.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

View more
  4 in total

1.  Graft versus host disease after liver transplantation following radiotherapy for the treatment of hepatocellular carcinoma: A case report and literature review.

Authors:  Zijun Chen; Chuangye Han; Xiangkun Wang; Yongfei He; Tianyi Liang; Shutian Mo; Xuan Li; Guangzhi Zhu; Hao Su; Xinping Ye; Zili Lv; Liming Shang; Zhang Wen; Minhao Peng; Tao Peng
Journal:  SAGE Open Med Case Rep       Date:  2022-05-24

Review 2.  Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.

Authors:  Vikrant Rai; Joe Abdo; Abdullah N Alsuwaidan; Swati Agrawal; Poonam Sharma; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-07       Impact factor: 3.842

3.  Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge.

Authors:  Jerry Yung-Lun Chin; Jiayi Gong; Edward Gane
Journal:  ACG Case Rep J       Date:  2020-12-21

4.  Graft Versus Host Disease After Intestinal Transplantation: A Single-center Experience.

Authors:  Stuart S Kaufman; Elsadig Hussan; Alexander Kroemer; Olga Timofeeva; Helena B Pasieka; Juan Francisco Guerra; Nada A Yazigi; Khalid M Khan; Udeme D Ekong; Sukanya Subramanian; Jason S Hawksworth; Raffaelle Girlanda; Shahira S Ghobrial; Thomas M Fishbein; Cal S Matsumoto
Journal:  Transplant Direct       Date:  2021-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.